You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
科倫博泰生物(06990.HK)藥物佳泰萊獲授予突破性療法認定
科倫博泰生物-B(06990.HK)公佈,公司靶向人滋養細胞表面抗原2(TROP2)的抗體偶聯藥物(ADC)蘆康沙妥珠單抗(sac-TMT)(佳泰萊),聯合抗程序性細胞死亡配體1(PD-L1)單克隆抗體塔戈利單抗(科泰萊)一線治療無驅動基因突變的局部晚期或轉移性非鱗狀非小細胞肺癌(NSCLC)獲國家藥監局藥品評審中心授予突破性療法認定。 集團指,這是蘆康沙妥珠單抗(sac-TMT)獲國家藥監局授予的第5項突破性療法認定。截止目前,蘆康沙妥珠單抗(sac-TMT)的2項適應症已於中國獲批上市。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account